Risk of Tuberculosis and Hepatitis B Reactivation in Patients With Crohn's Disease on Ustekinumab: A Nationwide Real-World Study.

Rongbei LiuZhilun LiLingna YeJing HuJian TangBaili ChenXiuli ChenBei TanYubei GuChen XieChunhui OuyangXiaomei SongFan LiYanyun FanHaixia RenLiangru ZhuMin ChenWenyu JiangQian Cao

Published in: Inflammatory bowel diseases (2023)

UST was safe for treatment of CD because no patient developed tuberculosis, persistent hepatitis, or acute liver failure during therapy, whether with a prophylactic regimen or not, based on our sample size and limited follow-up time.

Keyphrases

liver failure
hepatitis b virus
mycobacterium tuberculosis
pulmonary tuberculosis
hiv aids
case report
stem cells
emergency department
intensive care unit
respiratory failure